ImmunoGen, Inc. Announces FDA Acceptance of IND for Company’s Novel EGFR-Targeting ADC, IMGN289

barbara.lempert •    Novel antibody-drug conjugate (ADC) IMGN289 on track to begin human clinical testing for treatment of EGFR-positive tumors in 4Q2013. •    IMGN289 is ...

QLT Announces Second Quarter 2013 Results

barbara.lempert VANCOUVER, British Columbia, Aug. 1, 2013 (GLOBE NEWSWIRE) — QLT Inc. (Nasdaq:QLTI) (TSX:QLT) (“QLT” or the “Company”) is a biotechnology ...

HBIO Reports Second Quarter 2013 Results

barbara.lempert HOLLISTON, Mass., Aug. 1, 2013 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools ...

OncoGenex Announces that the Spruce Clinical Trial Evaluating OGX-427 is Now Open for Enrollment

barbara.lempert OncoGenex Announces that the Spruce™ Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer is Now ...

Vical Reports Second Quarter 2013 Financial Results

barbara.lempert Vical Reports Second Quarter 2013 Financial Results, Projects Phase 3 Data Release in August and Establishes Quiet Period SAN DIEGO, Aug. 1, 2013 (GLOBE NEWSWIRE) ...

Pharmanest meets all efficacy and safety end points in Phase II study of SHACT

barbara.lempert STOCKHOLM – August 1, 2013. Pharmanest AB announced today positive results from a Phase II-study investigating the efficacy and tolerability of SHACT. The data show ...

EpiCept Reports Second Quarter 2013 Operating and Financial Results

barbara.lempert Special August 6 Stockholder Meeting to Approve Final Conditions to Merger with Immune Pharmaceuticals TARRYTOWN, N.Y., Aug. 1, 2013 /PRNewswire/ — EpiCept Corporation ...

Nuvo Research announces 2013 second quarter results

barbara.lempert MISSISSAUGA, ON, July 31, 2013 /CNW/ – Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the ...

Medicines Co. wraps $240M deal to buy ProFibrix following PhIII success

John Carroll FierceBiotech News

SIGA Selects Lead Candidate for Dengue Antiviral Program

barbara.lempert NEW YORK, Aug. 1, 2013 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (Nasdaq:SIGA) today announced that it has selected a lead candidate for its dengue fever antiviral ...

InnoPharma Inc. Appoints Deborah DuFresne as Vice President, Strategic Portfolio Selection & Management

barbara.lempert PISCATAWAY, N.J., Aug. 5, 2013 (GLOBE NEWSWIRE) — InnoPharma, Inc. today announced the appointment of Deborah DuFresne to the role of Vice President, Strategic ...

Drug shortage complicates execution schedule for death penalty leader Texas

Eric Palmer A Texas Department of Criminal Justice official acknowledged that the state's current supply of pentobarbital will reach its expiry date in September when its next execution ...
Page 30 of 38« First...1020...2829303132...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS